Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Better together? Ibrutinib and venetoclax for high-risk CLL

Ibrutinib, a BTK inhibitor, and venetoclax, a BCL-2 inhibitor, are part of regimens approved for the treatment of patients with chronic lymphocytic leukemia (CLL). Here, Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the Phase II trial (NCT02756897) assessing the combination of these treatments, which show great synergy when modelled, and non-overlapping toxicity and mechanisms of action, for high-risk CLL patients in the frontline setting. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Jain discusses the promising efficacy and safety of this combination, which offers a chemotherapy-free treatment option for high risk patients.